Literature DB >> 3266031

Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases.

A J Swaak1, A van Rooyen, E Nieuwenhuis, L A Aarden.   

Abstract

Interleukin-6 (IL-6) is a monokine with a number of biological activities, which are intimately related to inflammatory responses. We have measured IL-6 levels in synovial fluid (SF) and serum (Se) of patients with rheumatic diseases. SF-IL-6 levels were a thousand-fold higher than corresponding Se levels and a positive correlation was found between SF and Se levels suggesting that Se-IL-6 is derived from IL-6 produced in the joint. Se levels of IL-6 were also positively correlated to C-reactive protein (CRP) levels, supporting the in vitro experiments showing that IL-6 stimulates hepatocytes to produce CRP. Finally we observed a positive correlation between SF-IL-6 levels and the local activity score.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3266031     DOI： 10.3109/03009748809098809

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


  25 in total

1.  Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.

Authors:  E Choy
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis.

Authors:  G Vreugdenhil; B Löwenberg; H G van Eijk; A J Swaak
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy.

Authors:  S Ohshima; Y Saeki; T Mima; M Sasai; K Nishioka; H Ishida; M Shimizu; M Suemura; R McCloskey; T Kishimoto
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

4.  Evaluation of interleukin-6 in rheumatoid arthritis as an activity criterion.

Authors:  T Sentürk; G Kinikli; M Turgay; H Tutkak; M Duman; G Tokgöz
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

5.  Adhesion-dependent activation of mucosal interleukin-6 production.

Authors:  H Linder; I Engberg; H Hoschützky; I Mattsby-Baltzer; C Svanborg
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

6.  Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity.

Authors:  B F DiCosmo; G P Geba; D Picarella; J A Elias; J A Rankin; B R Stripp; J A Whitsett; R A Flavell
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

7.  Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Authors:  R Madhok; A Crilly; J Watson; H A Capell
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

8.  Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy.

Authors:  Lene Surland Knudsen; Merete Lund Hetland; Julia Sidenius Johansen; Henrik Skjødt; Niels Daugaard Peters; Ada Colic; Karin Grau; Hans Jørgen Nielsen; Mikkel Ostergaard
Journal:  Biomark Insights       Date:  2009-09-23

9.  Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus.

Authors:  K P Metsärinne; D C Nordström; Y T Konttinen; A M Teppo; F Y Fyhrquist
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

10.  Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis.

Authors:  U Sack; R W Kinne; T Marx; P Heppt; S Bender; F Emmrich
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.